A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...

Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...

The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.

Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for left bundle branch block in heart failure.

New research highlights postnatal regeneration limits and pathological remodeling of the cardiac conduction system after myocardial infarction, uncovering mechanisms behind clinical arrhythmogenesis ...

OmniaSecure is now the first defibrillation lead approved for placement in the left bundle branch.

Please provide your email address to receive an email when new articles are posted on . Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area ...

Researchers have produced the most detailed and comprehensive human Heart Cell Atlas to date, including the specialized tissue of the cardiac conduction system -- where the heartbeat originates. In a ...

A Baylor College of Medicine multi-institution, collaborative study to determine the effectiveness and safety of commonly used pacing treatments for cardiac resynchronization therapy in people with ...

New research in Sweden has produced a "blueprint" revealing how the human heart is built during prenatal development. It offers insights that could lead to improved prenatal care and new treatments ...